Glycolytic-pathway inhibition and CTLA-4 blockade to improve immuno-oncology
In this Q&A, Dr Taha Merghoub discusses how a combination of glycolytic-pathway inhibition and immune checkpoint blockade using anti-CTLA-4 in patients with highly glycolytic tumours could present a personalised approach for immuno-oncology.